Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View EMMA insider activity ↗

EMMAEmmaus Life Sciences, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$7.49M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$12.45MYear ended December 31, 2025
Profit or loss-$7.49MYear ended December 31, 2025
Cash from the business-$11KYear ended December 31, 2025
Total assets$16.37MAs of June 30, 2026
Total liabilities$82.55MAs of June 30, 2026
Cash & equivalents$2.81MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$16.46M
2018-12
$22.75M
2019-12
$23.17M
2020-12
$20.61M
2021-12
$18.39M
2022-12
$29.6M
2023-12
$16.65M
2024-12
$12.45M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$12,453,000March 31, 202610-K ↗
January 1, 2024 – December 31, 2024$16,653,000March 31, 202610-K ↗
January 1, 2023 – December 31, 2023$29,597,000April 14, 202510-K ↗
January 1, 2022 – December 31, 2022$18,390,000July 3, 202410-K ↗
January 1, 2021 – December 31, 2021$20,610,000March 31, 202310-K ↗
January 1, 2020 – December 31, 2020$23,167,000March 31, 202210-K ↗
January 1, 2019 – December 31, 2019$22,752,000August 10, 202110-K/A ↗
January 1, 2018 – December 31, 2018$16,459,000January 25, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 15, 2026

Response SHA-256: 17a0e00ebefc084a552aa5eee008f384d4ffcc14ecda3109b6fc4e736255806b

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.